Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: twentyfirstcenturyfox who wrote (7069)	4/2/2001 6:23:00 PM
From: Ron Nairn	Read Replies (2) \| Respond to of 14101

After hours N/R. Second Aqua draw for $900,000. newswire.ca the bolded part is my favourite DIMETHAID RESEARCH INC. Canadian Quotes from Telenium DMX. (TSE) -------------------------------------------------------------------------------- Attention Business Editors: Dimethaid draws $900,000 against its financing facility TORONTO, April 2 /CNW/ - Dimethaid Research Inc. (TSE: DMX) announced today that it has effected a second draw pursuant to its January 2001 private placement agreement with Acqua Wellington North American Equities Fund, Ltd. The Company issued Acqua Wellington an additional 129,573 shares of common stock and received net proceeds of $900,000. The proceeds from today's draw will be used for general corporate purposes as the Company prepares to launch PENNSAID(R) Topical Solution in the European Union and in North America. PENNSAID(R) was launched in the United Kingdom last week by Provalis Healthcare Ltd, a division of Provalis Plc (LSE: PRO, NASDAQ SC: PVLS). "There are an estimated 7 million osteoarthritis sufferers in the U.K. who now have a treatment alternative that offers effective pain relief without any of the numerous side effects associated with currently available pills, including NSAIDs and COX-2 inhibitors," said Rebecca Keeler, President and CEO. "With the launch of PENNSAID(R) in the U.K., we have moved from 'mission to market,' and are targeting additional milestones as we expand our commercialization efforts. The flexibility of the Acqua Wellington financing allows us confidently to move forward with our strategic plans." Dimethaid Research Inc. is a pharmaceutical company engaged in the development and commercialization of innovative therapeutic products that offer the potential to minimize the unwanted systemic effects of drug therapy on the body. Dimethaid's proprietary drug delivery technology utilizes the cell's tubule system to deliver drugs cell-to-cell. As a result, patients are able to treat localized conditions, such as osteoarthritis, while limiting the body's absorption of, and associated risks from, the medication. This technology has been applied first to produce PENNSAID(R) Topical Solution. The Company's business development strategy is to leverage its proprietary transdermal delivery technology into additional commercial products. For additional information on the Company, please visit www.dimethaid.com. This release may contain forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors outside of management's control that could cause actual results to differ materially from those expressed in the forward-looking statements. A discussion of such risk factors is included in the Company's AIF filed with the OSC and includes, without limitation, risks regarding product development, clinical trials, dependence on third parties for development and licensing arrangements, and risks involving regulatory approval of products, licenses and patents. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect subsequent events or circumstances. %SEDAR: 00002418E -30- For further information: Dimethaid Research Inc., Tel. (905) 415-1446, info@dimethaid.com; Lippert/Heilshorn & Associates: Kim Golodetz, Tel. (212) 838-3777; Bruce Voss, Tel. (310) 691-7100. Archived images on this organization are available through CNW E-Pix at www.newswire.ca. Images are free to members of The Canadian Press. To request a free copy of this organization's annual report, please go to www.newswire.ca and click on reports@cnw. DIMETHAID RESEARCH INC. has 56 releases in this database. Rondo